01 1Onbrez Breezhaler
02 5Onbrez Breezhaler/Arcapta Neohaler
03 5Ultibro Breezhaler
04 2Ultibro Group
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 623
2019 Revenue in Millions : 630
Growth (%) : -1
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2022 Revenue in Millions : 479
2021 Revenue in Millions : 584
Growth (%) : -18
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2014 Revenue in Millions : 14.60%
2013 Revenue in Millions :
Growth (%) :
Indacaterol / Glycopyrronium Bromide
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2014 Revenue in Millions : 1866.70%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2015 Revenue in Millions : 220
2014 Revenue in Millions : 166
Growth (%) : -25%
Indacaterol And Glycopyrronium Bromide
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2016 Revenue in Millions : 363
2015 Revenue in Millions : 260
Growth (%) : 40
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2016 Revenue in Millions : 143
2015 Revenue in Millions : 166
Growth (%) : -14
Indacaterol and Glycopyrronium Bromide
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2017 Revenue in Millions : 411
2016 Revenue in Millions : 363
Growth (%) : 13
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2017 Revenue in Millions : 112
2016 Revenue in Millions : 143
Growth (%) : -22
Indacaterol And Glycopyrronium Bromide
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2018 Revenue in Millions : 454
2017 Revenue in Millions : 411
Growth (%) : 10%
LOOKING FOR A SUPPLIER?
